Loading Events

« All Events

  • This event has passed.


March 11, 2021 @ 10:00 am - 11:00 am

Scientists around the world agree—the microbiome is a critical and emerging tool in drug development for many disease areas and therapeutic modalities. From neuroscience to oncology and even soil science, the microbiome holds great promise for better patient outcomes. This field has exploded in the last 10-years providing opportunities for interdisciplinary collaborations and new startups. What have we learned, where are we now and what does the next generation of microbiome research look like? Join us to hear from top industry experts and learn how the microbiome can accelerate your drug to market. Your gut instinct is right—you don’t want to miss this exploration into the new frontier of drug discovery.



Graziella Amarasinghe, PhD, Head, Mktg & Sales, Microbiome Services Group at MilliporeSigma

Graziella Amarasinghe, Ph.D. is the Head of Marketing & Sales for the Microbiome Services Group at MilliporeSigma. Prior to this role, she led the marketing of the ADME Tox portfolio or primary and engineered cell lines for drug discovery scientists performing pre-clinical investigations of small molecule safety and toxicity. Before she joined MilliporeSigma, Graziella worked for Corning Life Sciences and received her Ph.D. and Post-Doctorate training at Washington University School of Medicine in St. Louis, Missouri.

Ravi Kiron, PhD, MBA, Head, BioPharma External Innovation, EMD Serono

Dr. Kiron is an experienced pharma/biotech executive with decades of experience from early drug discovery through late-stage clinical development, intellectual property, regulatory strategy and product commercialization. He currently serves as Head of BioPharma External Innovation at EMD Serono, the biopharmaceutical division of Merck KGaA. Dr. Kiron has consulted for dozens of life sciences companies, founded and led multiple new ventures, was an EIR at SRI Ventures, and serves currently on many company and non-profit boards. Dr. Kiron has also held operational & executive roles at Pfizer and J&J/Alza in cardiovascular and oncology R&D and strategic business development.

Paul E. Carlson, Jr., PhD, Principal Investigator, FDA

Paul Carlson is a principal investigator in the Laboratory of Mucosal Pathogens and Cellular Immunology in the Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review. He received his Ph.D. from the University of Pittsburgh and performed postdoctoral research at the University of Michigan. Since starting his laboratory at FDA in 2015, Dr. Carlson’s research has focused on infections caused by the enteric pathogens Clostridium difficile and Vancomycin resistant Enterococcus species. Dr. Carlson is co-chair of the FDA microbiome working group and the Joint Agency Microbiome (JAM) working group, as well as a member of the Microbiome Interagency Working Group.

Ravid Straussman MD, PhD, Senior Scientist, Weizmann Institute of Science

Dr. Ravid Straussman graduated from the MD/PhD program of Hadassah Medical School, Israel and an internship at Rabin Medical Center. In 2013, after completing a post-doc at the Broad institute of Harvard and MIT, he joined the Weizmann Institute as a principal investigator. The Straussman lab studies the tumor microenvironment and the tumor microbiome with a special focus on how non-cancer components in the tumor microenvironment affect the response of cancer cells to cytotoxic, targeted and immune-mediated anti-cancer therapies.


March 11, 2021
10:00 am - 11:00 am


Instrument Kit03